Cellular reprogramming to reverse disease and aging
Altos Labs is a longevity biotech pursuing cellular rejuvenation programming to restore cell health and resilience. It launched in 2021 with roughly $3B in funding and an all-star scientific roster.
Biotech📍 San Francisco, CAFounded 2021
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Altos Labs going public?
No. Altos Labs is private and has not filed to go public. There is no S-1 on file.
What is Altos Labs' valuation in 2026?
No confirmed valuation is on record for Altos Labs. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Altos Labs filed an S-1?
No public S-1 is on file for Altos Labs.
Can you buy Altos Labs stock?
No. Altos Labs is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Altos Labs on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Hal Barron
Founded
2021
HQ
San Francisco, CA
Total Raised
$3.0B
IPO Status
private
Fundraising Status
privateTotal raised $3.0B
Secondary Market
Implied price / share
$15.57
Open interest
6
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Altos Labs — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-26% vs 2026-08
Open roles
17
via greenhouse
Product-build share
59%
engineering, research, product, design
Trajectory
tightening
product-led hiring — 59% of open roles build product; the rest are go-to-market and G&A.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical Veterinarian, Part-time ContractDirector / Senior Director, Machine Learning for BiologyNeuroscience Research Associate / Research SpecialistResearch Specialist / Scientist, Assay DevelopmentScientist, Biological SciencesScientist I, Disease Biology
Counted from Altos Labs's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Products
Cellular reprogramming / rejuvenation research
Competitors
Retro Biosciences · NewLimit · Calico
BiotechLongevityCellular ReprogrammingDeep Tech
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.